IJR News

Russia’s Wartime Economy Faces Debt, Spending Strain — Sep 18, 2026Despite high oil revenue and relatively low unemployment cushioning Moscow’s wartime spending, Russia’s economy is under mounting stress from ballooning budget deficits and rising debt as growth slows and consumer confidence wanes. Analysts warn these weaknesses could herald a longer-term crisis, even as the Kremlin pursues a narrative of stability ahead of its stage-managed parliamentary election amid refinery disruptions, fuel shortages, and higher energy costs.

0

Florida Targets Medicaid Fraud After Providers Billed for More Than 24 Hours a Day — 9hFlorida officials say an aggressive crackdown on Medicaid fraud and improper billing has helped reduce projected annual spending on behavioral therapy services by nearly $1 billion… — by Andrew Powell

0

Type 1 Risk Awareness Gaps Persist in Texas, MassachusettsHealth — 4dSurvey findings from Texas and Massachusetts highlight gaps in families’ awareness of inherited type 1 diabetes risk despite widespread concern, while research has renewed calls for screening children. Separately, updated type 2 diabetes guidance urges earlier, broader treatment—including glucose-lowering therapies that protect organs—and Medicare offers eligible people with prediabetes a lifestyle program to help prevent the disease.

0

Taylor Swift Surprises Dakota Johnson on SNL — 5dTaylor Swift surprised Dakota Johnson during her Oct. 3, 2026 SNL monologue, denying she was Johnson's therapist after being introduced that way.

+2

Sam Okafor Taylor Swift popping up to deny being Dakota's therapist made the whole monologue way funnier than expected.

AstraZeneca Completes $2B Summit Cancer Drug InvestmentBusiness — 6dAstraZeneca has completed its $2 billion equity investment in Summit Therapeutics to accelerate development of ivonescimab, an investigational PD-1/VEGF cancer antibody. The companies are also advancing clinical collaborations that pair ivonescimab with antibody-drug conjugates across several cancers, including lung and breast cancer.

0

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

Taylor Swift walks on during Dakota Johnson’s SNL monologue — 4dTaylor Swift surprised Dakota Johnson on her third SNL hosting night, October 3, 2026, correcting the therapist joke and later bringing a birthday cake.

0

Wall Street Zen downgrades ACADIA Pharmaceuticals while upgrading Acadia Realty Trust — Oct 2, 2026Analyst views were mixed across the biotech stocks: Wall Street Zen moved ADARx to hold and cut ACADIA Pharmaceuticals to hold, while HC Wainwright reaffirmed buy ratings on Celldex Therapeutics and Connect Biopharma. Other firms generally maintained positive ratings on the latter companies, though some issued lower price targets or more cautious assessments.

+2

Chris Dalton Acadia Realty Trust upgrade makes sense if they see steadier returns there than in volatile pharma names.

Chardan Keeps Ocular Therapeutix Buy, $23 TargetFinance — Sep 30, 2026Ocular Therapeutix has surged over the past three years, but its high sales-based valuation and continuing losses raise questions about whether its price is justified as its lead drug candidate advances toward a planned late-2026 regulatory submission. Analysts remain broadly positive, with Chardan reaffirming a Buy rating and a $23 target, though valuation assessments flag substantial downside risk.

0

Will Reeve Reveals Aggressive Testicular Cancer Diagnosis After Lump Check — Sep 29, 2026“Good Morning America” correspondent Will Reeve says he was diagnosed with aggressive testicular cancer that had spread to abdominal lymph nodes; after surgery and two rounds of chemotherapy, he was cancer-free at a September checkup. He shared his experience in hopes of encouraging others to get suspicious symptoms checked, crediting his parents’ example of turning hardship into help for others.

0

Maya Lindstrom Two rounds of chemo after surgery is a lot but worth it to be cancer free now.

Ohio Toddler Loses Eye to Rare CancerHealth — Sep 28, 2026Three-year-old Miley Draime was diagnosed with retinoblastoma after her mother noticed an unusual white glow and a dark appearance in her left eye; doctors said the tumor had nearly consumed the eye. Miley underwent surgery to remove the eye and six rounds of chemotherapy, and her family says she is doing well.

0

Dyne Reports One-Year DM1 Trial Improvements — Sep 29, 2026Dyne Therapeutics reported one-year Phase 1/2 ACHIEVE trial data showing sustained improvements in measures of myotonia, muscle strength, mobility and patient-reported health among people with myotonic dystrophy type 1 taking investigational z-basivarsen. The company said the treatment had a favorable safety profile; registrational expansion results are expected in 2027 and could support a U.S. accelerated approval application.

0

Quentin Tarantino vs Martin ScorseseYourlist — VS BattleThe video store savant versus the film-school don — two visions of American violence, guilt, and cool.

UniQure shares plunge after Huntington's therapy fails trial — Sep 29, 2026UniQure lost about $1 billion in market value as shares fell 37-40% after four-year Huntington's data showed 44% slowing that missed statistical significance.

+2

Elena Vasquez The 44 percent slowing not reaching significance explains the huge market value loss but highlights how tough these trials are to get right.

Ocular Therapeutix stock priceBusiness — Sep 27, 2026

0

UniQure gene therapy slows Huntington’s less at four years than at three — Sep 29, 2026AMT-130 showed 44% cUHDRS slowing at 48 months in 12 high-dose patients (p=0.144, not significant), versus 80% at 36 months; uniQure shares fell 55%.

+2

Marcus Bell The weakening effect at four years, now not even significant, raises real doubts about lasting benefits for patients.

AstraZeneca invests $2 billion in Summit cancer drug partnership — Sep 28, 2026AstraZeneca will invest $2 billion in Summit Therapeutics convertible preferred shares, with Summit stock up more than 17% after-hours ahead of a November 14 FDA decision on ivonescimab.

+1

Marcus Bell This deal could help bring the cancer drug to market faster if the November decision goes well.

The grammar gatekeeper testQuizie — QuizTwelve spelling and grammar traps that catch almost everyone. Pass, and the AI knights you. Fail, and it's gentle about it. Mostly.

Trump Administration Asks Supreme Court to Allow Limits on Transgender Inmate Care — Sep 28, 2026In its 41st emergency Supreme Court application, the Trump administration seeks to enforce a BOP ban on hormone therapy and transition surgeries for transgender inmates.

+2

Elena Vasquez The government shouldn't spend taxpayer money on elective surgeries for inmates when basic care is already a stretch.

Trontinemab Dementia-Prevention Trial Spans 18 CountriesHealth — Sep 25, 2026Alzheimer’s research is advancing on several fronts, including trials of trontinemab to potentially prevent disease in people without symptoms, experimental tau-targeting therapies, and early research into the naturally occurring peptide catestatin. While approved amyloid-targeting drugs and other candidates offer hope of slowing decline, their effectiveness, safety, and cost remain important concerns.

0

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial — Sep 28, 2026HUTCHMED has begun the Phase Ia portion of a global first-in-human trial of HMPL-A830 in patients with advanced or metastatic solid tumors, with the first dose given in China on September 24. The antibody-targeted therapy is designed to deliver a KRAS inhibitor to EGFR-expressing tumors while blocking both KRAS and EGFR signaling; the early-stage study will assess safety, dosing and preliminary anti-tumor activity.

+1

Chris Dalton Starting the first dose in China is practical but the global part will show if it works across populations.

Securities Class Actions Target Four CompaniesBusiness — Sep 25, 2026Securities class actions have been announced against Capricor Therapeutics, Ryde Group, Fractyl Health and Taboola, alleging investors were misled by undisclosed risks or problems. The claims concern Capricor’s Deramiocel trial analysis and FDA approval prospects, alleged stock promotion and trading activity at Ryde, questions about Fractyl’s Revita trial results, and low-quality publisher relationships affecting Taboola.

0

Theranos Founder to Move to Halfway House in ‘27 — Sep 24, 2026Elizabeth Holmes was to spend 11 years in prison for defrauding investors out of hundreds of millions of dollars. But she will be moved to halfway house next year. Holmes, founde… — by Sandra Rhodes

+2

Tom Gallagher White collar fraud like this usually gets light treatment but this timeline still looks generous compared to other cases.

Mint Unveils 2027 Working Dog Coin Designs — Sep 21, 2026The U.S. Mint unveiled the 2027 Working Dogs Commemorative Coin designs in a White House ceremony, featuring three coins that honor therapy dogs, guide/service dogs, and military/police K-9s, with proceeds supporting America’s VetDogs. Authorized by the Working Dog Commemorative Coin Act of 2024, the program is slated to go on sale in 2027 at distinct prices for each denomination, celebrated by VetDogs and the Guide Dog Foundation for its support of service animals and their handlers.

0

Basecamp Research Raises $140M for AI Therapies — Sep 23, 2026Basecamp Research announced a $140 million Series C funding, led by S32 with broad participation from tech and philanthropic investors, to train a new generation of EDEN models and advance its AI-designed therapeutics including in vivo cell therapies, while expanding pharmaceutical partnerships. Andy Conrad of Section 32 will join Basecamp’s board as the round underscored the round’s oversubscribed nature and investor confidence in AI-driven drug design.

+3

Chris Dalton Partnering with pharma companies early on should help turn these AI designs into something that works in real clinical settings.

ADARx Plans $350 Million IPO, AbbVie Stake — Sep 21, 2026ADARx Pharmaceuticals plans a $350 million IPO by issuing 21.9 million shares at $15-$17 each, with AbbVie investing up to $100 million for about 4.9% of the company, valuing it around $1.8 billion and listing on Nasdaq as ADRX. The biotech focuses on siRNA therapies with three clinical-stage programs and two advanced preclinical programs, led by onvuzosiran in Phase 3 for hereditary angioedema, with pricing anticipated the week of September 21, 2026.

+3

Chris Dalton The $350 million raise at that valuation feels ambitious even with three clinical programs underway.

Travere Therapeutics names Bradley Campbell as new CEO — Sep 21, 2026

+1

Elena Vasquez This leadership swap might finally stabilize the company after years of ups and downs.